ArticleBMC complementary and alternative medicine2018
Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice.
Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Green Tea Catechins Significantly Reduce Zika Virus in RBCs Through Viral Inactivation.Pathogens (Basel, Switzerland) · 2026Article
- Traditional Chinese Medicine in Chronic Hepatitis B: Integrating Antiviral Effects and Immune Modulation in the Context of T Cell Exhaustion.Drug design, development and therapy · 2026Review
- Research Progress on the Protective Effect of Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) on the Liver.Nutrients · 2025Review
- Article
- Antiviral Effects and Mechanisms of Active Ingredients in Tea.Molecules (Basel, Switzerland) · 2024Review
- An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action.Frontiers in cellular and infection microbiology · 2024Review
- First study onVeterinary world · 2023Article
- Inhibition of macrophages inflammasome activationFrontiers in immunology · 2023Article
- The progress of molecules and strategies for the treatment of HBV infection.Frontiers in cellular and infection microbiology · 2023Review
- The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma.Frontiers in pharmacology · 2023Review
- Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation.American journal of cancer research · 2023Article
- Curcumin inhibited hepatitis B viral entry through NTCP binding.Scientific reports · 2021Article
- Anti-hepatitis B activities of Myanmar medicinal plants: a narrative review of current evidence.Virusdisease · 2021Review
- Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor.Cell & bioscience · 2021Article
- Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2.Medical hypotheses · 2020Article
- (-)-Epigallocatechin-3-gallate induces interferon-λ2 expression to anti-influenza A virus in human bronchial epithelial cells (BEAS-2B) through p38 MAPK signaling pathway.Journal of thoracic disease · 2020Article
- ERK1/2-HNF4α axis is involved in epigallocatechin-3-gallate inhibition of HBV replication.Acta pharmacologica Sinica · 2020Article
- Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Article
- Advances in the Antagonism of Epigallocatechin-3-gallate in the Treatment of Digestive Tract Tumors.Molecules (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundPersistent hepatitis B virus (HBV) infection causes liver cirrhosis and hepatocellular carcinoma and constitutes a major worldwide health problem. Currently, anti-HBV drugs are limited to peginterferon and nucleos(t)ide analogs, which are costly and have considerable side effects; the development of novel, effective anti-HBV agents is crucial.
methodsCatechins are a major group of compounds found in green tea extract and epigallocatechin gallate (EGCG) has been shown to have antiviral properties, including inhibition of cellular entry by HBV. FRG (Fah
resultsHere, we show the inhibitory effect of EGCG on HBV infection and replication in HuS-E/2 cells. The inhibitory effect of EGCG on HBV infection in vivo was confirmed by monitoring HBV DNA and HBsAg in serum and immunostaining the liver tissues of the human liver chimeric mice.
conclusionsThe effects of EGCG suggest a robust strategy for the treatment of HBV infection and EGCG may have therapeutic potential for the treatment of HBV-associated liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.